SEC Form 4 · accession 0000886163-18-000145
LIGAND PHARMACEUTICALS INC · LGND
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Todd C Davis
Director
Period of report
Oct 8, 2018
Accepted (ET)
Oct 9, 2018 · 4:24 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000886163
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Oct 8, 2018 | S | 2,500 | $253.9912 | D | 42,556 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sale(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on September 06, 2018, in accordance with Rule 10b5-1.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $250.48 to $256.77, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.